Cargando…
Paracrine Mechanisms of Intravenous Bone Marrow-Derived Mononuclear Stem Cells in Chronic Ischemic Stroke
BACKGROUND: The emerging role of stem cell technology and transplantation has helped scientists to study their potential role in neural repair and regeneration. The fate of stem cells is determined by their niche, consisting of surrounding cells and the secreted trophic growth factors. This interim...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5123023/ https://www.ncbi.nlm.nih.gov/pubmed/27846623 http://dx.doi.org/10.1159/000446404 |
_version_ | 1782469673961390080 |
---|---|
author | Bhasin, Ashu Srivastava, M.V. Padma Mohanty, Sujata Vivekanandhan, Sivasubramaniam Sharma, Sakshi Kumaran, Senthil Bhatia, Rohit |
author_facet | Bhasin, Ashu Srivastava, M.V. Padma Mohanty, Sujata Vivekanandhan, Sivasubramaniam Sharma, Sakshi Kumaran, Senthil Bhatia, Rohit |
author_sort | Bhasin, Ashu |
collection | PubMed |
description | BACKGROUND: The emerging role of stem cell technology and transplantation has helped scientists to study their potential role in neural repair and regeneration. The fate of stem cells is determined by their niche, consisting of surrounding cells and the secreted trophic growth factors. This interim report evaluates the safety, feasibility and efficacy (if any) of bone marrow-derived mononuclear stem cells (BM-MNC) in chronic ischemic stroke by studying the release of serum vascular endothelial growth factor (VEGF) and brain-derived neurotrophic growth factor (BDNF). METHODS: Twenty stroke patients and 20 age-matched healthy controls were recruited with the following inclusion criteria: 3 months to 1.5 years from the index event, Medical Research Council (MRC) grade of hand muscles of at least 2, Brunnstrom stage 2-5, conscious, and comprehendible. They were randomized to one group receiving autologous BM-MNC (mean 60-70 million) and to another group receiving saline infusion (placebo). All patients were administered a neuromotor rehabilitation regime for 8 weeks. Clinical assessments [Fugl Meyer scale (FM), modified Barthel index (mBI), MRC grade, Ashworth tone scale] were carried out and serum VEGF and BDNF levels were assessed at baseline and at 8 weeks. RESULTS: No serious adverse events were observed during the study. There was no statistically significant clinical improvement between the groups (FM: 95% CI 15.2-5.35, p = 0.25; mBI: 95% CI 14.3-4.5, p = 0.31). VEGF and BDNF expression was found to be greater in group 1 compared to group 2 (VEGF: 442.1 vs. 400.3 pg/ml, p = 0.67; BDNF: 21.3 vs. 19.5 ng/ml) without any statistically significant difference. CONCLUSION: Autologous mononuclear stem cell infusion is safe and tolerable by chronic ischemic stroke patients. The released growth factors (VEGF and BDNF) in the microenvironment could be due to the paracrine hypothesis of stem cell niche and neurorehabilitation regime. |
format | Online Article Text |
id | pubmed-5123023 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-51230232016-12-05 Paracrine Mechanisms of Intravenous Bone Marrow-Derived Mononuclear Stem Cells in Chronic Ischemic Stroke Bhasin, Ashu Srivastava, M.V. Padma Mohanty, Sujata Vivekanandhan, Sivasubramaniam Sharma, Sakshi Kumaran, Senthil Bhatia, Rohit Cerebrovasc Dis Extra Original Paper BACKGROUND: The emerging role of stem cell technology and transplantation has helped scientists to study their potential role in neural repair and regeneration. The fate of stem cells is determined by their niche, consisting of surrounding cells and the secreted trophic growth factors. This interim report evaluates the safety, feasibility and efficacy (if any) of bone marrow-derived mononuclear stem cells (BM-MNC) in chronic ischemic stroke by studying the release of serum vascular endothelial growth factor (VEGF) and brain-derived neurotrophic growth factor (BDNF). METHODS: Twenty stroke patients and 20 age-matched healthy controls were recruited with the following inclusion criteria: 3 months to 1.5 years from the index event, Medical Research Council (MRC) grade of hand muscles of at least 2, Brunnstrom stage 2-5, conscious, and comprehendible. They were randomized to one group receiving autologous BM-MNC (mean 60-70 million) and to another group receiving saline infusion (placebo). All patients were administered a neuromotor rehabilitation regime for 8 weeks. Clinical assessments [Fugl Meyer scale (FM), modified Barthel index (mBI), MRC grade, Ashworth tone scale] were carried out and serum VEGF and BDNF levels were assessed at baseline and at 8 weeks. RESULTS: No serious adverse events were observed during the study. There was no statistically significant clinical improvement between the groups (FM: 95% CI 15.2-5.35, p = 0.25; mBI: 95% CI 14.3-4.5, p = 0.31). VEGF and BDNF expression was found to be greater in group 1 compared to group 2 (VEGF: 442.1 vs. 400.3 pg/ml, p = 0.67; BDNF: 21.3 vs. 19.5 ng/ml) without any statistically significant difference. CONCLUSION: Autologous mononuclear stem cell infusion is safe and tolerable by chronic ischemic stroke patients. The released growth factors (VEGF and BDNF) in the microenvironment could be due to the paracrine hypothesis of stem cell niche and neurorehabilitation regime. S. Karger AG 2016-10-19 /pmc/articles/PMC5123023/ /pubmed/27846623 http://dx.doi.org/10.1159/000446404 Text en Copyright © 2016 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. |
spellingShingle | Original Paper Bhasin, Ashu Srivastava, M.V. Padma Mohanty, Sujata Vivekanandhan, Sivasubramaniam Sharma, Sakshi Kumaran, Senthil Bhatia, Rohit Paracrine Mechanisms of Intravenous Bone Marrow-Derived Mononuclear Stem Cells in Chronic Ischemic Stroke |
title | Paracrine Mechanisms of Intravenous Bone Marrow-Derived Mononuclear Stem Cells in Chronic Ischemic Stroke |
title_full | Paracrine Mechanisms of Intravenous Bone Marrow-Derived Mononuclear Stem Cells in Chronic Ischemic Stroke |
title_fullStr | Paracrine Mechanisms of Intravenous Bone Marrow-Derived Mononuclear Stem Cells in Chronic Ischemic Stroke |
title_full_unstemmed | Paracrine Mechanisms of Intravenous Bone Marrow-Derived Mononuclear Stem Cells in Chronic Ischemic Stroke |
title_short | Paracrine Mechanisms of Intravenous Bone Marrow-Derived Mononuclear Stem Cells in Chronic Ischemic Stroke |
title_sort | paracrine mechanisms of intravenous bone marrow-derived mononuclear stem cells in chronic ischemic stroke |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5123023/ https://www.ncbi.nlm.nih.gov/pubmed/27846623 http://dx.doi.org/10.1159/000446404 |
work_keys_str_mv | AT bhasinashu paracrinemechanismsofintravenousbonemarrowderivedmononuclearstemcellsinchronicischemicstroke AT srivastavamvpadma paracrinemechanismsofintravenousbonemarrowderivedmononuclearstemcellsinchronicischemicstroke AT mohantysujata paracrinemechanismsofintravenousbonemarrowderivedmononuclearstemcellsinchronicischemicstroke AT vivekanandhansivasubramaniam paracrinemechanismsofintravenousbonemarrowderivedmononuclearstemcellsinchronicischemicstroke AT sharmasakshi paracrinemechanismsofintravenousbonemarrowderivedmononuclearstemcellsinchronicischemicstroke AT kumaransenthil paracrinemechanismsofintravenousbonemarrowderivedmononuclearstemcellsinchronicischemicstroke AT bhatiarohit paracrinemechanismsofintravenousbonemarrowderivedmononuclearstemcellsinchronicischemicstroke |